Table 2 Baseline characteristics of patients aged 50–74 years in the two cohorts
Variables | Chinese cohort (N = 550) | Swedish cohort (N = 544) | P value |
|---|---|---|---|
Demographics | Â | Â | Â |
Age, years* | Â | Â | Â |
 Mean (SD) | 63.6 ± 6.8 | 65.3 ± 6.4 |  < 0.001 |
 Median (IQR) | 64 (59–69) | 67 (60–70) |  < 0.001 |
Female, n (%)* | 251 (45.6) | 152 (27.9) |  < 0.001 |
Clinical history, n (%) | Â | Â | Â |
Ischemic heart disease* | 99 (18.0) | 177 (32.5) |  < 0.001 |
Dilated cardiomyopathy | 138 (25.1) | 66 (12.1) |  < 0.001 |
Hypertension | 190 (34.5) | 294 (54.0) |  < 0.001 |
Valvular disease | 183 (33.3) | 169 (31.1) | 0.435 |
Atrial fibrillation/ flutter* | 229 (41.6) | 241 (44.3) | 0.373 |
Diabetes mellitus* | 172 (31.3) | 187 (34.4) | 0.275 |
Pulmonary disease | 66 (12.0) | 115 (21.1) |  < 0.001 |
Anemia* | 199 (36.2) | 191 (35.1) | 0.711 |
Physical/laboratory | Â | Â | Â |
SBP, mmHg* | 114.0 ± 15.3 | 123.0 ± 19.1 |  < 0.001 |
DBP, mmHg | 69.6 ± 9.9 | 72.6 ± 10.7 |  < 0.001 |
Heart rate, beats/min* | 82.8 ± 19.9 | 70.9 ± 13.4 |  < 0.001 |
Hemoglobin, g/L | 130.4 ± 24.0 | 132.4 ± 18.9 | 0.271 |
eGFR, ml/min/1.73m2* | 71.7 ± 25.0 | 67.8 ± 25.2 | 0.027 |
NT-proBNP, | 3121 | 3000 | 0.119 |
Median (IQR), pg/mL* | (1418–7693) | (1096–7296) |  |
LVEF < 40%* | 235 (42.7) | 272 (50.0) | 0.016 |
QRS duration ≥ 120 ms, n (%)* | 174 (31.6) | 183 (33.6) | 0.48 |
LBBB, n (%) | 110 (20.0) | 54 (9.9) |  < 0.001 |
Medication, n (%) | Â | Â | Â |
ACEIs / ARBs* | 275 (50.0) | 492 (90.4) |  < 0.001 |
Beta-blockers* | 333 (60.5) | 503 (92.5) |  < 0.001 |
Aldosterone antagonists* | 377 (68.5) | 196 (36.0) |  < 0.001 |
Diuretics | 411 (74.7) | 350 (64.3) |  < 0.001 |
Digitalis | 224 (40.7) | 71 (13.1) |  < 0.001 |
Device therapy, n (%) | Â | Â | Â |
Pacemaker | 18 (3.3) | 48 (8.8) |  < 0.001 |
CRT-P/D | 42 (7.6) | 18 (3.3) | 0.002 |
ICD | 31 (5.6) | 17 (3.1) | 0.043 |